NCT04463134

Brief Summary

Non-tuberculous mycobacterial (NTM) infection is becoming more and more common, especially causing pulmonary diseases in those elderly or the immunocompromised. The diagnosis, treatment and monitoring of NTM pulmonary disease(NTMPD) are not updated and real life management if also challenging.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2020

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 29, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 9, 2020

Completed
23 days until next milestone

Study Start

First participant enrolled

August 1, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2023

Completed
Last Updated

July 14, 2020

Status Verified

July 1, 2020

Enrollment Period

2 years

First QC Date

June 29, 2020

Last Update Submit

July 12, 2020

Conditions

Keywords

Disease progression, death

Outcome Measures

Primary Outcomes (1)

  • Clinical outcomes of NTMPD patients with or without treatment in 1 year

    Clinical outcomes include stable disease, disease progression, chest infection, death.

    1 year

Secondary Outcomes (4)

  • Clinical parameters that predict the disease progression

    1 year

  • Functional

    1 year

  • Microbiological parameters that predict disease progression

    1 year

  • Radiological features that predict disease progression

    1 year

Study Arms (2)

Treatment group

They will start pharmacological treatment according to guidelines and sensitivity

Drug: NTM drug treatment

Observation group

They will not start pharmacological treatment. They will be monitored on symptoms, sputum conversion and radiological progression

Interventions

NTM drug treatment according to guideline and sensitivity test results

Also known as: pharmacological treatment
Treatment group

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults suspected NTMPD followed up in the Prince of Wales Hospital will be recruited

You may qualify if:

  • Patients aged 18 or above
  • Two or more respiratory samples positive for NTM, including sputum, tracheal aspirates, bronchial washing, bronchial aspirates, bronchial trap and bronchoalveolar lavage or lung biopsy

You may not qualify if:

  • NTM isolates from extrapulmonary samples
  • Refused to sign an informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (23)

  • Falkinham JO 3rd. Environmental sources of nontuberculous mycobacteria. Clin Chest Med. 2015 Mar;36(1):35-41. doi: 10.1016/j.ccm.2014.10.003. Epub 2014 Nov 6.

    PMID: 25676517BACKGROUND
  • Gebert MJ, Delgado-Baquerizo M, Oliverio AM, Webster TM, Nichols LM, Honda JR, Chan ED, Adjemian J, Dunn RR, Fierer N. Ecological Analyses of Mycobacteria in Showerhead Biofilms and Their Relevance to Human Health. mBio. 2018 Oct 30;9(5):e01614-18. doi: 10.1128/mBio.01614-18.

    PMID: 30377276BACKGROUND
  • Gupta RS, Lo B, Son J. Phylogenomics and Comparative Genomic Studies Robustly Support Division of the Genus Mycobacterium into an Emended Genus Mycobacterium and Four Novel Genera. Front Microbiol. 2018 Feb 13;9:67. doi: 10.3389/fmicb.2018.00067. eCollection 2018.

    PMID: 29497402BACKGROUND
  • Henkle E, Winthrop KL. Nontuberculous mycobacteria infections in immunosuppressed hosts. Clin Chest Med. 2015 Mar;36(1):91-9. doi: 10.1016/j.ccm.2014.11.002. Epub 2014 Dec 23.

    PMID: 25676522BACKGROUND
  • Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014 Mar;6(3):210-20. doi: 10.3978/j.issn.2072-1439.2013.12.24.

    PMID: 24624285BACKGROUND
  • Zweijpfenning SMH, Ingen JV, Hoefsloot W. Geographic Distribution of Nontuberculous Mycobacteria Isolated from Clinical Specimens: A Systematic Review. Semin Respir Crit Care Med. 2018 Jun;39(3):336-342. doi: 10.1055/s-0038-1660864. Epub 2018 Aug 2.

    PMID: 30071548BACKGROUND
  • Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010 Oct 1;182(7):970-6. doi: 10.1164/rccm.201002-0310OC. Epub 2010 Jun 10.

    PMID: 20538958BACKGROUND
  • Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan. Emerg Infect Dis. 2016 Jun;22(6):1116-7. doi: 10.3201/eid2206.151086. No abstract available.

    PMID: 27191735BACKGROUND
  • Kim HO, Lee K, Choi HK, Ha S, Lee SM, Seo GH. Incidence, comorbidities, and treatment patterns of nontuberculous mycobacterial infection in South Korea. Medicine (Baltimore). 2019 Nov;98(45):e17869. doi: 10.1097/MD.0000000000017869.

    PMID: 31702652BACKGROUND
  • Morimoto K, Iwai K, Uchimura K, Okumura M, Yoshiyama T, Yoshimori K, Ogata H, Kurashima A, Gemma A, Kudoh S. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014 Jan;11(1):1-8. doi: 10.1513/AnnalsATS.201303-067OC.

    PMID: 24102151BACKGROUND
  • Vinnard C, Longworth S, Mezochow A, Patrawalla A, Kreiswirth BN, Hamilton K. Deaths Related to Nontuberculous Mycobacterial Infections in the United States, 1999-2014. Ann Am Thorac Soc. 2016 Nov;13(11):1951-1955. doi: 10.1513/AnnalsATS.201606-474BC.

    PMID: 27607541BACKGROUND
  • Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. doi: 10.1164/rccm.200604-571ST. No abstract available.

    PMID: 17277290BACKGROUND
  • Hwang JA, Kim S, Jo KW, Shim TS. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017 Mar 8;49(3):1600537. doi: 10.1183/13993003.00537-2016. Print 2017 Mar.

    PMID: 28275170BACKGROUND
  • Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis. 2017 Feb 1;64(3):301-308. doi: 10.1093/cid/ciw723. Epub 2016 Nov 10.

    PMID: 28011609BACKGROUND
  • Igari H, Yamagishi K, Yamazaki S, Murata S, Yahaba M, Takayanagi S, Kawasaki Y, Taniguchi T. A retrospective observational study of antimicrobial treatment for non-tuberculous mycobacteria disease using a nationwide claims database in Japan. J Infect Chemother. 2020 Apr;26(4):349-352. doi: 10.1016/j.jiac.2019.10.009. Epub 2019 Nov 11.

    PMID: 31727566BACKGROUND
  • van Ingen J, Wagner D, Gallagher J, Morimoto K, Lange C, Haworth CS, Floto RA, Adjemian J, Prevots DR, Griffith DE; NTM-NET. Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases. Eur Respir J. 2017 Feb 15;49(2):1601855. doi: 10.1183/13993003.01855-2016. Print 2017 Feb. No abstract available.

    PMID: 28182571BACKGROUND
  • Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012 Apr 15;185(8):881-6. doi: 10.1164/rccm.201111-2016OC. Epub 2012 Feb 3.

    PMID: 22312016BACKGROUND
  • Shah NM, Davidson JA, Anderson LF, Lalor MK, Kim J, Thomas HL, Lipman M, Abubakar I. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect Dis. 2016 May 6;16:195. doi: 10.1186/s12879-016-1521-3.

    PMID: 27154015BACKGROUND
  • Thomson R, Donnan E, Konstantinos A. Notification of Nontuberculous Mycobacteria: An Australian Perspective. Ann Am Thorac Soc. 2017 Mar;14(3):318-323. doi: 10.1513/AnnalsATS.201612-994OI.

    PMID: 28118021BACKGROUND
  • Ide S, Nakamura S, Yamamoto Y, Kohno Y, Fukuda Y, Ikeda H, Sasaki E, Yanagihara K, Higashiyama Y, Hashiguchi K, Futsuki Y, Inoue Y, Fukushima K, Suyama N, Kohno S. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One. 2015 May 28;10(5):e0128304. doi: 10.1371/journal.pone.0128304. eCollection 2015.

    PMID: 26020948BACKGROUND
  • Ding LW, Lai CC, Lee LN, Hsueh PR. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. Epidemiol Infect. 2006 Oct;134(5):1060-7. doi: 10.1017/S0950268805005698. Epub 2006 Feb 22.

    PMID: 16492317BACKGROUND
  • Park YS, Lee CH, Lee SM, Yang SC, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Rapid increase of non-tuberculous mycobacterial lung diseases at a tertiary referral hospital in South Korea. Int J Tuberc Lung Dis. 2010 Aug;14(8):1069-71.

    PMID: 20626955BACKGROUND
  • Stout JE, Koh WJ, Yew WW. Update on pulmonary disease due to non-tuberculous mycobacteria. Int J Infect Dis. 2016 Apr;45:123-34. doi: 10.1016/j.ijid.2016.03.006. Epub 2016 Mar 11.

    PMID: 26976549BACKGROUND

MeSH Terms

Conditions

Disease ProgressionDeath

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident

Study Record Dates

First Submitted

June 29, 2020

First Posted

July 9, 2020

Study Start

August 1, 2020

Primary Completion

July 31, 2022

Study Completion

July 31, 2023

Last Updated

July 14, 2020

Record last verified: 2020-07

Data Sharing

IPD Sharing
Will not share